Azithromycin Cas number: 83905-01-5 Molecular Formula： C38H72N2O12
| Melting Point | 115°C |
| Density | 1.18 g/cm³ |
| storage temp | Inert atmosphere,Room Temperature 2-8°C |
| solubility | DMF: 16 mg/ml DMSO: 5 mg/mlm Ethanol: 16 mg/ml Ethanol:PBS(pH 7.2) (1:1): 0.50 mg/ml |
| optical activity | N/A |
| Appearance | White Powder |
| Purity | ≥98% |
Manus Aktteva Biopharma LLP, a Global sourcing company and a supplier of Azithromycin (CAS No.: 83905-01-5) offers for your requirements of RND / Development quantities or commercials, based on status of the product.
DISCLAIMER : While all due diligence possible will be done and we will cooperate on all matters if any problem arises during course of sourcing , we cannot be held responsible for any noncompliance or complications in transaction that may happen, which is beyond our control.Products falling in to controlled substance category / list of schedule drugs shall be exported directly from the manufacturer principals only against receipt of original import permission issued by concerned authorities of the importing country.• Kindly note that we are working with full legal compliance and do not breach any laws regionally or globally. Our public records speak about our credibility. We do not encourage or want to be part of any private or public organizations to prove our compliances.
PATENTS Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer''s risk. Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271 +A13(1)•Manus Aktteva Biopharma LLP assumes no responsibility/liability in case of being imparted with goods which infringe intellectual property in any manner whatsoever which includes patent rights of any individual. Manus Aktteva Biopharma LLP makes no representations or warranties of any kind, express or implied, about the originality or reliability with respect to the intellectual property which includes patents in its products or services for any purpose. Manus Aktteva Biopharma LLP warns the sellers not to sell any goods which infringe intellectual property in any manner whatsoever which includes patent rights of any individual. Manus Aktteva Biopharma LLP warns the buyers not to use/procure any goods to achieve a product which might be knowingly causing an infringement of intellectual property in any manner whatsoever which includes patent rights of any individual.
Azithromycin is a semi-synthetic, ring-expanded erythromycin produced by a Beckmann rearrangement of erythromycin oxime and reduction to the imine ether, followed by reductive methylation. Azithromycin was the first of the azalides and was designed to improve the stability and biological half-life of erythromycin A, as well as improve activity against Gram negative bacteria. Since its discovery in 1980 by Djokic and co-workers, azithromycin has enjoyed considerable therapeutic success.
